Study S002413

A Phase 1 Randomized, Single-blind, Placebo-controlled, First-in-Human and Sequential Group Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 Following Single Ascending Doses Via Oral Administration

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05694741
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: TERMINATED
Enrollment: 31
Start: 2022-12-20
Primary completion: 2023-05-10
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:AZD0186; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Adverse Events (AEs), and Serious Adverse Events (SAEs) [Up to the Follow-up Visit (approximately 6 weeks)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002394	Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist. Qi W, The Journal of pharmacology and experimental therapeutics	2025	Other trial	PMID 41015846 DOI	cites ClinicalTrials.gov:NCT05694741